CASI CASI Pharmaceuticals Inc.

+0.22  (+6%)
Previous Close 3.6
Open 3.6
Price To Book 3.16
Market Cap 357504307
Shares 93,587,515
Volume 196,156
Short Ratio
Av. Daily Volume 347,522

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 completed. Will not further development.
Cancer - Advanced/Metastatic Soft Tissue Sarcoma
Phase 2 initiated July 2012. Noted April 14, 2017 that further patient enrollment has been stopped.
Cancer - triple-negative breast cancer
Phase 2 initiated October 2015.
Cancer - fibrolamellar carcinoma (FLC)

Latest News

  1. CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Confirmatory Clinical Trial For ZEVALIN®
  2. CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference
  3. These 4 Healthcare Stocks Are Heating Up
  4. Do Institutions Own Shares In CASI Pharmaceuticals, Inc. (NASDAQ:CASI)?
  5. The 4 Healthcare Stocks To Watch On Monday
  6. CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®)
  7. Chinese biotech stocks hit by a double whammy, which means it’s time to buy
  8. Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developments
  9. CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China
  10. CASI Pharmaceuticals Announces Third Quarter and First Nine Months 2018 Financial and Business Results
  11. Today’s Research Reports on Stocks to Watch: CASI Pharmaceuticals and Therapix Biosciences
  12. Why CASI Pharmaceuticals Inc. Is Rocketing Higher Today
  13. 3 Healthcare Stocks Trending Higher On News
  14. CASI Pharmaceuticals Acquires HBV ANDA from Laurus Labs Limited
  15. CASI Pharmaceuticals Announces Appointment Of President To Its China Operations To Lead Commercialization
  16. CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer
  17. CASI Pharmaceuticals Announces $48.5 Million Private Placement
  18. CASI Pharmaceuticals Announces Second Quarter And First Half 2018 Financial And Business Results